French startup Sonomind says it has raised €20 million (about $21.6 million) to speed development of a new, noninvasive approach aimed at treatment-resistant depression—using low-intensity focused ultrasound to target specific brain regions involved in mood regulation.
The company is pitching the technique as an alternative to more invasive options, emphasizing that it requires no surgery and no implanted electrodes.
Targeting depression that doesn’t respond to medication
Sonomind is focused on treatment-resistant depression, defined here as cases in which at least two lines of drug treatment have failed to produce a sufficient effect. The company points to a global patient population estimated at “several tens of millions,” a group for whom available options remain limited and often invasive.
Its proposed solution relies on low-intensity focused ultrasound neuromodulation, a fast-growing research area drawing increasing interest in clinical neuroscience. Sonomind says the key advantages are precise targeting and the absence of side effects associated with drug treatments or electrical interventions.
Bpifrance backs the round
The €20 million (about $21.6 million) fundraising was completed with support from Bpifrance, France’s state-backed public investment bank—an institutional signal of confidence in the technology’s potential.
The financing blends medtech and neurotechnology, two sectors where France is seeking to strengthen its position against U.S. and U.K. players, according to the article.
Clinical trials and industrial scale-up next
Sonomind said the new funding will be used to continue clinical trials and to structure its industrial development. The startup did not provide a timeline for bringing the technology to market or specify which geographies it plans to prioritize.
A crowded investment theme, but a less crowded niche
Digital mental health and neurotechnology have attracted significant investment in recent years, but noninvasive solutions aimed specifically at treatment-resistant depression remain rare, the article says.
Sonomind is positioning itself in a segment with limited direct competition, even as companies such as Neuralink and Medtronic work on broader neuromodulation approaches. With €20 million (about $21.6 million) and backing from Bpifrance, the startup now has a window to validate its approach clinically before the space becomes more structured.
